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Association Between Cognitive Function andQuality of Life
in PatientsWith Head and Neck Cancer
AmyM.Williams, PhD; Jamie Lindholm, MS, CCC-SLP; Diana Cook, MS, CCC-SLP; Farzan Siddiqui, MD, PhD;
Tamer A. Ghanem, MD, PhD; Steven S. Chang, MD
IMPORTANCE There is a dearth of research examining the associations between cognitive
function and quality of life (QoL) in patients with head and neck cancer (HNC), despite much
research examining QoL and some research examining cognitive function in this population.
OBJECTIVE To identify the associations between cognitive functioning and QoL in patients
prior to treatment for HNCwithin a multidisciplinary care team.
DESIGN, SETTING, AND PARTICIPANTS Case series with planned data collection of cognitive
function, QoL, and psychosocial variables at an urbanMidwest academic medical center
including 83 patients with a diagnosis of HNC between August 2015 and December 2016 who
underwent a pretreatment assessment with a clinical health psychologist and a speech and
language pathologist.
MAIN OUTCOMES ANDMEASURES At pretreatment assessment, theMontreal Cognitive
Assessment and Functional Assessment of Cancer Therapy–Head & Neck, version 4, were
administered along with a semistructured interview to gather data on psychiatric symptoms,
social support, and substance use. Patient demographic, clinical, and psychosocial variables
were extracted via medical record review.
RESULTS Of 83 patients (64 [77%]male; mean age, 59.54 [95% CI, 57.23-61.73] years),
cognitive impairment was identified in 55% (n = 46) at pretreatment. Number of depressive
symptoms (mean, 2.43 [95% CI, 2.06-2.89] symptoms) was associated with impairments in
delayed recall (r = −0.28; 95% CI, −0.47 to −0.07) and all domains of QoL. Cognitive
impairment in delayed recall was associated with lower QoL in both overall QoL and the
domains of emotional and functional well-being. Current benzodiazepine use, history of
heavy alcohol use, and current and past tobacco use were also associated with lower QoL in
specific domains.
CONCLUSIONS AND RELEVANCE Cognitive impairment is common in patients with HNC and is
associated with QoL and psychosocial variables. Together with previous research indicating
that cognitive function and QoL can influence treatment adherence and outcomes, the
results argue for the incorporation of cognitive screening and QoL assessment as part of
pretreatment assessment for patients.
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C hanges in cognition are common with normative ag-ing.However, cognitive impairment represents a rangein cognition from more substantial than normative
changes andup to themanifestationsofdementia.1 Thepreva-
lence of cognitive impairment in excess of normative changes
due to aging is estimated at 16% to 22%of the population.1 As
would be expected, the risks of cognitive impairment in-
crease with age, with those older than 65 years having an in-
cidence of 14 to 111 per 1000 patient-years.2,3 Cognitive im-
pairment is also associated with sex (ie, more common in
men),4 lower level of education attainment, tobacco use, and
heavy alcohol use.5 There also exists a bidirectional relation-
ship between psychiatric factors and cognitive impairment,
with premorbid recurrent depression being an identified
contributing factor to cognitive impairment and those with
cognitive impairment having a higher risk of developing
depression.6-8 Anxiety has also been associated with higher
risk of cognitive impairment.3,5
Previous researchhas foundthatcognitive impairmentwas
associated with substance abuse, psychiatric symptoms, and
quality of life (QoL) in othermedical disorders, includingneu-
rological disorders9-11 and cancers.12,13 Cognitive impairment
has also been associated with important treatment variables
such as treatment adherence for rehabilitation and outcomes
in patients with cancer.14 In particular, cognitive impairment
at cancer treatment initiation was associated with a 6 times
higher risk of death in patients with breast, prostate, or colo-
rectal cancers.15 Additionally, both cognitive impairment and
poorer QoL have separately been associated with decreased
overall survival in patients with cancer.12-14 While there ex-
ists significant previous research examining QoL in patients
with head andneck cancers (HNCs) and someexamining cog-
nitive function in patients with HNC, there is a dearth of re-
search examining the associations between QoL and cogni-
tive function in this population.
Head and neck cancer represents 3% of all malignant
neoplasms in the United States.1 Head and neck cancer typi-
cally presents in an older population and is more common in
men and in those with tobacco and/or alcohol use15-18—all of
which are also risk factors for cognitive impairment.2-5
Previous research has determined that patient-reported
cognitive functioning prior to HNC treatment is indepen-
dently associated with disease progression and survival.19
Additionally, in research examining cognitive function prior
to induction chemotherapy or chemoradiation treatment for
HNC, up to 47% of patients demonstrated cognitive impair-
ment on neuropsychological tests.20 However, these studies
often rely on long neuropsychological test batteries or
patient self-report. Whereas previous cross-sectional and
longitudinal research has examined patient self-reported
cognitive impairment and QoL in patients with HNC, these 2
variables have not been examined in relation to one
another.20-23
To address the dearth of research examining the asso-
ciations between QoL and cognitive function in patients
with HNC, the present study sought to better elucidate the
associations between cognitive functioning and QoL in
patients prior to treatment for head and neck cancer within
a multidisciplinary care team. We also worked to identify
patient and clinical correlates associated with both cogni-
tive function and QoL.
Methods
Approvalwithwaiver of consentwasobtained fromtheHenry
FordHealthSystemInstitutionalReviewBoard for a retrospec-
tivemedical recordreviewofpatientvariablesandselectedout-
comes. All patients with a diagnosis of oral cavity, orophar-
ynx, hypopharynx, or larynx HNC between August 2015 and
December 2016, regardless ofmedical and/or neurological co-
morbidities,whohadbothapretreatment semistructuredpsy-
chosocial interview and cognitive assessment with a clinical
health psychologist and completed the Functional Assess-
ment of Cancer Therapy–Head & Neck version 4 (FACT-H&N)
during pretreatment assessment with the speech and lan-
guage pathologist were included in analyses. Further patient
demographic information and treatment variables, including
clinical staging at initial presentation, treatment recommen-
dations, and adherence to these recommendations were ob-
tainedviamedical record review.All psychosocial andpsychi-
atric variables were gathered during the evaluation with the
health psychologist using a semistructured clinical interview.
Psychosocial variables included current and past alcohol
use, tobacco use, illicit drug use, and social support. Social
supportwasdichotomizedasadequateor inadequate,withad-
equate support indicating that thepatienthadperceivedemo-
tional and instrumental (eg, transportation,helpathome) sup-
port available. Psychiatric variables included current and
previouspsychiatric care andpsychotropicmedicationuse, as
well as current and baseline psychiatric symptoms. Depres-
sionwasassessedasa symptomcountbasedonDiagnostic and
Statistical Manual of Mental Disorders (Fifth Edition) criteria,
and anxietywas assessed as a presence or absence of general-
ized anxiety symptoms prior to cancer diagnosis. Adherence
to treatment recommendations was defined as completing
treatment as recommended. Those patients who did not re-
ceive the full treatment as recommended by the multidisci-
plinary tumor board were considered nonadherent, regard-
less of reason for this nonadherence.
Key Points
Question What are the associations between cognitive
functioning and quality of life (QoL) in patients prior to treatment
for head and neck cancer within a multidisciplinary care team?
Findings In this case series of 83 adults evaluated before head
and neck cancer treatment, 46 (55%) had cognitive impairment.
The number of depressive symptoms was associated with
impairments in delayed recall and QoL; cognitive impairment and
delayed recall were associated with lower QoL; and past substance
use was associated with current QoL and cognitive function.
Meaning Cognitive impairment is common in patients with head
and neck cancer and is associated with QoL and psychosocial
variables.
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Montreal Cognitive Assessment
At pretreatment assessment, the clinical health psychologist
administered a brief screening tool for cognitive function, the
Montreal Cognitive Assessment (MoCA). The MoCA24 is a
cognitive screening instrument that takes 5 to 10 minutes to
administer. The MoCA has been validated against longer neu-
ropsychological test batteries typically used in other studies
that examined cognitive function in cancer treatment.25-27
The MoCA measures the cognitive domains of executive
functioning, attention and concentration, language, delayed
recall, abstraction, and orientation. Executive functioning
encompasses working memory, attentional and inhibitory
control, problem solving, and planning. It represents the cog-
nitive control over one’s behavior. Attention and concentra-
tion is the ability to selectively pay attention to one thing
while being able to ignore other stimuli. Language is a proxy
for crystalized memory, or memory for previously learned
material (ie, long-termmemory). Conversely, delayed recall is
a measure of short-term memory, or memory of newly
learned materials. Abstraction is a measure of one’s ability to
isolate common features among dissimilar objects or “think
outside the box.” Finally, orientation is composed of one’s
knowledge of time, place, and current context.24 Patients
with scores greater than 26 out of 30 are considered normal
or cognitively unimpaired.24,28 To aid in better understand-
ing of MoCA scores, previous research has shown that those
with Alzheimer disease have mean scores of 16 (range, 11-21)
and those with mild cognitive impairment have mean scores
of 22 (range, 19-25).28,29 In normal controls, the MoCA has
demonstrated similar sensitivity and specificity compared
with the more commonly used Mini–Mental State Examina-
tion (MMSE). However, the MoCA demonstrated improved
sensitivity and specificity in both mild cognitive impairment
and Alzheimer disease populations compared with the
MMSE.30-32 The MoCA was chosen for the purposes of this
study due to its sensitivity and specificity, as well as its brev-
ity, ease of use, multiple equivalent test forms allowing for
repeated testing, availability in vision- and hearing-impaired
versions and other languages, paper testing forms, and com-
mon use in other medical populations within our institution.
Functional Assessment of Cancer Therapy–
Head and Neck Cancer
TheFACT-H&N33 is avalidatedmeasureofQoL inpatientswith
HNC. The FACT-H&N is composed of 38 Likert-scored items,
with higher scores indicating better QoL. A total score on the
FACT-H&N can be calculated by summing the 5 domain sub-
scales: physicalwell-being, socialwell-being, emotionalwell-
being, functional well-being, and head and neck–specific
well-being.29TheFACT-H&Nis commonlyused in researchex-
aminingQoL inpatientswithHNCandwaschosen in this study
for the brevity of themeasure, the domain subscales, and the
utility in clinical practice.
Analytic Plan
Datawere analyzedusingSPSS statistical software (IBMCorp).
Descriptive statisticswere computed for all demographic and
cancer variables, substance use, psychiatric symptoms, QoL,
andMoCAscores. Student t testswereused for comparisonbe-
tween groups, and bivariate correlations were used for com-
parison between interval variables.
Results
Demographic Characteristics
Patients were a sample of 83 patients presenting for treat-
ment of HNC to the Department of Otolaryngology–Head and
Neck Surgery at an academicmedical center in aMidwest ur-
ban center. The patients’ mean age was 59.54 (95% CI, 57.23-
61.73)years.Additionaldemographic informationcanbe found
in Table 1.
Patients were assessed in the pretreatment clinic prior to
initiating treatment following presentation at a multidisci-
plinary tumorboard.Appropriate staging is determinedat the
tumorboard, and in this patient cohort, 60 (72%)patients had
a late-stagecancer (AmericanJointCommitteeonCancer stage
III-IV).Sixty-three (76%)ofpatients followedthetreatment rec-
ommendationsmade by the tumor board. Additional cancer-
specific and treatment variables can be found in Table 1.
Atpretreatment assessment, 25 (30%)patientswereusing
tobacco products and 61 (73%) patients had a history of to-
bacco use. Heavy alcohol usewas common,with 48 (58%) re-
porting past heavy alcohol use (ie, weekly binge drinking >5
standard drinks or more than recommended moderate alco-
hol useof 1 standarddrink/d forwomenor 2 standarddrinks/d
for men) and 23 (28%) reporting current heavy alcohol use
(Table2).Additionally, 12 (14%) reportedcurrent illicitdruguse
and 38 (46%) past illicit drug use, with the most common il-
licit drug being marijuana, followed by cocaine and heroin.
Overall, 46%(n = 38)ofpatients reportedapsychiatrichis-
tory,with 36% (n = 30) of all patients reporting elevatedbase-
line anxiety. At the time of assessment, patients reported a
meanof 2.43depressive symptoms (range,0-8) (Table 2),with
6% (n = 5) of all patients reporting 5ormoredepressive symp-
toms and 6% (n = 5) reporting passive suicidal ideation. De-
spite only 5% (n = 4) patients reporting current engagement
in mental health treatment (ie, being under the care of a psy-
chiatrist and/or engaged in psychotherapy), 21 (25%) patients
hadahistoryof takingpsychotropicmedications and27 (33%)
werecurrently takingapsychotropicmedication, typicallypre-
scribed by a nonpsychiatric clinician (Table 2).
In the present study, reliability of the MoCA was good
(Cronbach α = .77). Table 3 presents the MoCA total and sub-
scaledescriptives. In thepresent sample, themeanMoCAscore
was less than the cut scoreof 26outof 30, indicating thatmost
patients would be considered cognitively impaired. In par-
ticular, 45% (n = 37) scored in thenonimpaired range (ie, over-
all MoCA score ≥26). Fifty-five percent (n = 46) of all patients
scored in the impaired range,with 54% (n = 45) of all patients
scoring between 18 and 25 (ie, level of mild cognitive impair-
ment), and 1% (n = 1) between 10 and 17 (ie, level of Alzhei-
mer disease).
TheFACT-H&Nreliabilitywasacceptable togood,depend-
ing on the scale (overall QoL Cronbach α = .91, physical well-
being α = .66, social well-being α = .75, emotional well-being
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α = .67, functionalwell-being α = .89, head and neck–specific
well-being α = .82). Table 3 presents the FACT-H&N total and
subscale descriptives.
Cognitive Function andQoL
Patient scores on the language subscale were positively asso-
ciated with social QoL/well-being. Patient scores on delayed
recall were positively associatedwith overall QoL, emotional
QoL/well-being, and functionalQoL/well-being.Therewereno
other significant associations between MoCA total or sub-
scales and QoL scales (Table 4).
Cognitive Function, QoL, and Demographic and
Psychosocial Variables
Table 5 highlights the associations between cognitive func-
tion, QoL, and demographic variables. In particular, age was
negatively associated with executive function, delayed re-
call, and totalMoCA score, indicating that older patients have
increasing difficultywith these processes. Agewas also nega-
tively associatedwith head and neck–specific well-being. Pa-
tient level of education was positively associated with atten-
tion/concentration (r = 0.22; 95% CI, 0.02-0.40) and
abstraction (r = 0.23; 95%CI,0.03-0.42), indicating that those
with higher educational attainment demonstrated higher
scores in these processes.
Table 5 also highlights the associations between cogni-
tive function,QoL, andpsychosocial variables. Thenumberof
depression symptoms reported by patients was negatively
Table 1. Demographic and Cancer-Specific Variables
Variable
Value
(N = 83)
Age, y
Mean (95% CI) 59.54 (57.23-61.73)
Range 34-86
Sex, No. (%)
Female 19 (23)
Male 64 (77)
Race, No. (%)
White 63 (76)
African American 17 (20)
Other 3 (4)
Education, y
Mean (95% CI) 13.78 (13.31-14.48)
Range 9-21
Employment at diagnosis, No. (%)
Full or part time 34 (41)
Retired 30 (36)
Disability 13 (16)
Marital status, No. (%)
Married or partnered 54 (65)
Single or divorced 25 (30)
Widowed 4 (5)
Sufficient social support, No. (%) 75 (90)
American Joint Committee on Cancer stage, No. (%)
Early (stage I-II) 23 (28)
Late (stage III-IV) 60 (72)
Histopathologic subtype, No. (%)
Squamous cell carcinoma 76 (92)
Site, No. (%)
Oral cavity 27 (33)
Oropharynx 37 (45)
Laryngopharynx 16 (19)
Other head and neck cancer 3 (4)
Human papillomavirus type P16 positive, No. (%) 29 (35)
Followed tumor board instructions, No. (%) 63 (76)
Primary treatment, No. (%)
Radiotherapy 4 (5)
Chemoradiotherapy 26 (31)
Chemotherapy 2 (2)
Surgery 51 (61)
Adjuvant treatment, No. (%)
Any 33 (40)
Radiotherapy 16 (19)
Chemoradiotherapy 16 (19)
Chemotherapy 1 (1)
Table 2. Psychosocial Variables
Variable
Value
(N = 83)
Substance use, No. (%)
Heavy alcohol
Current 23 (28)
Past 48 (58)
Tobacco
Current 25 (30)
Past 61 (73)
Illicit drug
Current 12 (14)
Past 38 (46)
Type of illicit drug(s) reported, No. (%)
Marijuana 36 (43)
Cocaine 10 (12)
Heroin 4 (5)
Psychiatric symptoms
Depressive symptoms
Mean (95% CI) 2.43 (2.06-2.89)
Range 0-8
Anxiety, No. (%) 30 (36)
Trauma, No. (%) 10 (12)
Passive suicidal ideation, No. (%) 5 (6)
Psychotropic medication use, No. (%)
Past 21 (25)
Current
Any 27 (33)
Benzodiazepine 16 (19)
Antidepressant 18 (22)
Antipsychotic 2 (2)
Mental health treatment, No. (%)
Current 4 (5)
Past 25 (30)
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associated with delayed recall scores. Additionally, number
of depression symptoms was also negatively associated
with the overall QoL and each QoL/well-being subscale.
Higher baseline anxiety was associated with lower emo-
tional well-being and impairment in the language subscale.
Furthermore, current benzodiazepine use was associated
with lower overall, physical, emotional, and functional QoL/
well-being. As would be expected, lack of social support for
treatment was associated with lower social well-being
(t(81) = −3.36; P = .001; adequate support mean, 22.94; 95%
CI, 21.92 to 23.96; inadequate support mean, 17.73; 95% CI,
12.31 to 23.15), as well as greater impairment in delayed
recall (t(80) = 2.17; P = .03; adequate support mean, 2.68;
95% CI, 2.36 to 2.99; inadequate support mean, 3.86; 95%
CI, 2.50 to 5.21). Sex, current and past antidepressant use,
and past benzodiazepine use were not associated with
MoCA overall or subscales or with overall QoL or the well-
being scales.
Cognitive Function, QoL, and Substance Use
Table 5 demonstrates the associations between heavy alco-
hol, tobacco, and heavy drug use and the total and subscales
of both the MoCA and FACT-H&N. Patients with histories of
heavy alcohol use reported lower emotional, functional, and
headandneck–specificwell-being, aswell asoverallQoL/well-
being. Current tobacco use was associated with lower social,
functional, and overall QoL/well-being, as well as lower per-
formance on the language subscale. Past tobacco use was as-
sociatedwith lowerQoL/well-beingoverall andacross all sub-
scales. Past heavydrugusewas associatedwith lowerdelayed
recall, abstraction performance, and overall MoCA, as well as
lower functionalwell-being. Currentheavyalcohol andheavy
drug use were not associated with overall MoCA or subscales
or with overall QoL or the well-being scales.
Cognitive Function, QoL, and HNCVariables
Patients with human papillomavirus type p16–positive dis-
easereportedhighersocialwell-being(t(81) = 2.20;P = .03;p16-
positive mean, 23.95; 95% CI, 22.41 to 25.49; p16-negative
mean, 21.56; 95%CI, 20.18 to22.93). Stage atpresentationand
whether the patient followed tumor board recommendations
were not associated with overall MoCA or subscales or with
overall QoL or the well-being scales.
Discussion
The present study sought to better elucidate the associa-
tions between cognitive functioning and QoL in patients
prior to treatment for HNC within a multidisciplinary care
team. We also worked to identify patient and clinical corre-
lates associated with both cognitive function and QoL.
Slightly more than 50% of patients presented with at least
mild cognitive impairment at pretreatment assessment.
This is in proportion to previous findings of 47% of patients
presenting with cognitive impairment prior to treatment.20
As would be expected, cognitive impairment was related to
age and educational attainment.25
As with previous research in patients with non-HNC
disorders, cognitive impairment was associated with QoL in
Table 3. Descriptives forMontreal Cognitive Assessment (MoCA)
and Functional Assessment of Cancer Therapy–Head &Neck,
Version 4 (FACT-H&N)
Scale or Subscale (Maximum
Score) Mean (Range) (95% CI)
MoCA
Total (30) 24.63 (17-30) (23.97-25.72)
Executive function (5) 4.17 (1-5) (3.95-4.37)
Attention/concentration (6) 5.41 (2-6) (5.20-5.59)
Language (6) 4.84 (2-6) (4.60-5.07)
Abstraction (2) 1.21 (0-2) (1.04-1.37)
Free recall (5) 2.75 (0-5) (2.46-3.06)
Orientation (6) 5.89 (4-6) (5.80-5.96)
FACT-H&N
Total (148) 110.20 (60-143) (105.97-114.54)
Physical well-being (28) 22.97 (11-28) (22.15-23.79)
Social well-being (28) 22.54 (8-28) (21.47-23.46)
Emotional well-being (24) 17.67 (10-24) (16.90-18.44)
Functional well-being (28) 17.99 (4-28) (16.58-19.47)
Head and neck–specific
well-being (40)
29.04 (4-40) (27.44-30.76)
Table 4. Correlations BetweenMontreal Cognitive Assessment (MoCA) Total and Subscale Scores and Functional Assessment
of Cancer Therapy–Head &Neck, Version 4 (FACT-H&N), Scales
FACT-H&N
Scale or
Subscale
MoCA Scale or Subscale, Correlation (95% CI)
Total
Executive
Function
Attention and
Concentration Language Abstraction
Delayed
Recall Orientation
Total 0.20 (−0.03
to 0.42)
−0.002 (−0.19
to 0.21)
−0.03 (−0.28
to 0.26)
0.15 (−0.07
to 0.37)
0.13 (−0.10
to 0.33)
0.32 (0.13
to 0.51)
−0.13 (−0.28
to 0.02)
Physical
well-being
0.06 (−0.13
to 0.27)
−0.02 (−0.21
to 0.17)
−0.06 (−0.25
to 0.16)
0.08 (−0.10
to 0.27)
0.08 (−0.13
to 0.30)
0.12 (−0.09
to 0.34)
−0.02 (−0.14
to 0.12)
Social
well-being
0.20 (−0.03
to 0.44)
0.02 (−0.18
to 0.23)
0.02 (−0.20
to 0.29)
0.24 (0.06
to 0.44)
0.11 (−0.12
to 0.34)
0.23 (−0.004
to 0.45)
−0.20 (−0.30
to −0.08)
Emotional
well-being
0.11 (−0.08
to 0.31)
−0.005 (−0.17
to 0.18)
−0.05 (−0.29
to 0.21)
−0.06 (−0.27
to 0.16)
0.11 (−0.13
to 0.30)
0.26 (0.07
to 0.45)
0.03 (−0.24
to 0.27)
Functional
well-being
0.18 (−0.03
to 0.38)
0.01 (−0.18
to 0.19)
−0.11 (−0.33
to 0.15)
0.10 (−0.13
to 0.34)
0.14 (−0.09
to 0.33)
0.36 (0.16
to 0.53)
−0.11 (−0.28
to 0.03)
Head and
neck–specific
well-being
0.16 (−0.06
to 0.37)
−0.01 (−0.23
to 0.21)
0.05 (−0.19
to 0.33)
0.13 (−0.08
to 0.34)
0.06 (−0.16
to 0.26)
0.19 (0.02
to 0.36)
−0.11 (−0.28
to 0.10)
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patientswithHNC.9-13 In particular, language and delayed re-
call (ie, memory) were associated with poorer QoL in mul-
tiple domains. Interestingly, there were no significant rela-
tionships between cognitive impairment and QoL in the
physical or head and neck–specific domains. This may indi-
cate that impairments in cognitive function have a larger ef-
fect in thedomains of apatient’s life that are important topsy-
chosocial functioning, such as emotional functioning, daily
independence, and social support and engagement. It is also
likely that these areasmay influence thepatient’s ability to ap-
propriately engage in HNC care. Hence, this is an area for fu-
ture research.
Similar to previous research demonstrating a relation-
shipbetweenpsychiatricsymptoms,cognitive impairment,and
QoL,3,6-11 the present study found these associations, particu-
larly with depressive symptoms and anxiety. The consis-
tency in these associations within the research highlight the
importanceof cliniciansnot just identifyingpretreatmentpsy-
chiatric symptoms and monitoring for these symptoms
throughout cancer treatment, but also treating these appro-
priatelywith referral tobehavioralhealthcliniciansand/orpsy-
chotropic medications.
In contrast to previous research,23,34 cognitive impair-
ment in the present study was not related to heavy alcohol
use.Previous researchhasshownheavyalcoholuse tobeapre-
dictor of cognitive impairment.34 However, past heavy alco-
hol use was associated with poorer QoL across most do-
mains. Perhaps most notably, past heavy alcohol use was
associatedwithpoorer emotionalwell-being.This findingmay
indicate that patientswith heavy alcohol use are less likely to
have the coping strategies necessary to cope with their can-
cer diagnosis. This limitation in coping has been found to
interfere with engagement in treatment, adherence, and sur-
vival in cancer.12,23,35,36 Adding to the literature in this area,
thepresent studyalsodemonstrated thatpast tobaccousewas
associated with QoL.
Limitations
The present study is a case series of patients presenting for
treatment of HNC at a tertiary care center that practices mul-
tidisciplinary care. Whereas the field of HNC care is moving
toward specialty care at tertiary centers, this does not repre-
sent a majority of HNC care settings. Hence, there are some
limitations to the generalizability of the results that warrant
future research.Whereas theMoCA is a brief cognitive assess-
ment,making it clinicallyuseful indeterminingcognitive func-
tion and the need for further neuropsychological workup, it
is limitedbypatient engagement in testing, fatigue, andother
psychosocial variables. These limitations are true for most
forms of psychological assessment, and these limitations
shouldnot deter further investigationof cognitive function in
this population, particularly in light of research demonstrat-
ing the role of cognitive impairment in treatment adherence.
Additionally, medical comorbidities known to affect cogni-
tive function were not assessed in the present study and
future research should include comorbidities. Because the
present studywas cross-sectional, it canonlydemonstrate as-
sociations between variables, not directionality. Future re-
search should focusonprospective, longitudinal studies inpa-
tientswithHNCtoexamineQoL, aswell as cognitiveandmood
symptomchanges, across treatment andhowthesemayaffect
disease-free and overall survival.
Conclusions
Thedearthof researchexaminingtheassociationsbetweenQoL
and cognitive function in HNC highlights the need for re-
search to better elucidate the relationships among cognitive
impairment,QoL, andother psychosocial variableswithin the
context of treatment adherence andoutcomes. Increasedun-
derstandingof these factors and their interactionwith theabil-
ity to rehabilitate, morbidity, and mortality would aid in the
development of both medical and psychosocial interven-
tions that influence morbidity and mortality in this popula-
tion. Such intervention should likely start with identification
of risk factors, such as alcohol and tobacco use, in addition to
the cognitive impairment itself prior to treatment initiation,
thusallowing the treatment teamto interveneandpossibly im-
prove both patient and treatment outcomes (eg, QoL and
survival). Further research is needed in this area, particularly
with patients with HNC due to the high prevalence of comor-
bid substance use and psychiatric symptoms.
The present study sought to better elucidate the associa-
tions between cognitive functioning andQoL inpatients prior
to treatment forHNCwithinamultidisciplinarycare team.The
findings demonstrated the feasibility of assessing cognitive
functionwithin amultidisciplinary team, as well as the asso-
ciations between domains of cognitive impairment and areas
of QoL in patients with HNC. It further demonstrated impor-
tantassociationsbetweencognitive impairment,QoL,andpsy-
chosocial variables. The results argue for the incorporation of
cognitive screening andassessment ofQoLaspart of pretreat-
ment assessment for patients, as well as further research into
more direct, causal relationships via longitudinal, prospec-
tive studies.
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